MAPK3 and cancer: Concurrently, CP and PAL can also increase ERK1/2 activity in cancer cells, leading to LC3 activity, which, in coordination with JNK inhibiting bcl2 to release beclin 1 and upregulating autophagy-related protein 5 (ATG5), leads to the development of the nascent autophagosome [149,188,225].